|1.||Li, Juan: 4 articles (06/2009 - 12/2005)|
|2.||Heymans, Françoise: 4 articles (06/2009 - 12/2005)|
|3.||Shao, Biyun: 2 articles (06/2009 - 01/2008)|
|4.||Cui, Yongyao: 2 articles (06/2009 - 01/2008)|
|5.||Chen, Hongzhuan: 2 articles (06/2009 - 01/2008)|
|6.||Dong, Changzhi: 2 articles (06/2009 - 01/2008)|
|7.||Miezan Ezoulin, Jean-Marc: 2 articles (01/2008 - 02/2007)|
|8.||Dong, Chang-Zhi: 2 articles (02/2007 - 12/2005)|
|9.||Massicot, France: 2 articles (02/2007 - 12/2005)|
|10.||Chen, Hong-Zhuan: 2 articles (02/2007 - 12/2005)|
06/01/2009 - "PMS777 (1-100 microM) was found to inhibit Abeta-induced human neuroblastoma SH-SY5Y cell apoptosis in a concentration-dependent manner. "
01/01/2008 - "Continuing with our research, we further investigated the neuroprotective activities of PMS777 on PAF-triggered neuronal injury in human neuroblastoma SH-SY5Y cells. "
02/01/2007 - "PMS777 (1-100 microM) dose-dependently inhibited PAF-induced rabbit platelet aggregation by competing with [3H]PAF for its receptor on platelets, and protected a human neuroblastoma cell line SH-SY5Y against PAF-induced neurotoxicity. "
12/02/2005 - "Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells."
|2.||Alzheimer Disease (Alzheimer's Disease)
06/01/2009 - "These results suggest that PMS777 potently protects against Abeta-induced neuronal apoptosis and neuroinflammation, and warrants further investigations in connection with its potential value in the treatment of Alzheimer's disease."
02/01/2007 - "Taken together, these results demonstrate that PMS777 possesses dual activities for PAF receptor antagonism and AChE inhibition, suggesting that this compound may be a promising lead compound for further investigation related to the treatment for Alzheimer's disease."
|3.||Amnesia (Dissociative Amnesia)